MARKET

REPL

REPL

Replimune Group
NASDAQ
21.62
+1.60
+7.99%
After Hours: 21.85 +0.23 +1.06% 19:40 11/06 EST
OPEN
20.20
PREV CLOSE
20.02
HIGH
21.91
LOW
20.20
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
21.91
52 WEEK LOW
1.500
MARKET CAP
2.05B
P/E (TTM)
-7.7253
1D
5D
1M
3M
1Y
5Y
1D
What Just Happened With Replimune Group (REPL)?
Simply Wall St · 13h ago
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
Seeking Alpha · 1d ago
Narrower Losses Could Be A Turning Point For Replimune Group Stock (REPL)
Simply Wall St · 1d ago
Jim Cramer Recommends FedEx: ‘Very Nice Move Off The Bottom’
Benzinga · 2d ago
Is Replimune Group (REPL) Above Fair Value After A 119% Jump?
Simply Wall St · 3d ago
Replimune management to meet with Cantor
TipRanks · 4d ago
Big Pharma Has $1.2 Trillion to Spend and a Revenue Gap to Fill: Inside the F/m Emerald Life Sciences Innovation ETF (LFSC)
TipRanks · 4d ago
Replimune Group Consensus Price Target Increased by 14.78% to $22.44
NASDAQ · 4d ago
More
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Webull offers Replimune Group Inc stock information, including NASDAQ: REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.